Characterization of Patients with EGFR Mutation-Positive NSCLC Following Emergence of the Osimertinib Resistance Mutations, L718Q or G724S: A Multicenter Retrospective Observational Study in France
DOI: https://doi.org/10.2147/ott.s448909
IF: 4
2024-05-29
OncoTargets and Therapy
Abstract:Mateo Sanchis-Borja, 1 Florian Guisier, 2 Aurélie Swalduz, 3 Hubert Curcio, 4 Victor Basse, 5 Christophe Maritaz, 6 Christos Chouaid, 1 Jean-Bernard Auliac 1 1 Pulmonology Department, Créteil Intercommunal Hospital, Créteil, France; 2 Normandie Univ, UNIROUEN, LITIS Laboratory QuantIF team EA4108, CHU Rouen, Department of Pneumology and Inserm CIC-CRB 1404, Rouen, France; 3 Department of Medical Oncology, Léon Bérard Cancer Center, Lyon, France; 4 Department of Medical Oncology, Centre François Baclesse, Caen, France; 5 Department of Oncology CHU Morvan, Brest, France; 6 Medical Affairs Department, Oncology, Boehringer Ingelheim France, Paris, France Correspondence: Jean-Bernard Auliac, Pulmonology Department, Créteil Intercommunal Hospital, Créteil, France, Email Purpose: The third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), osimertinib, is an effective first-line therapy for patients with common EGFR mutation-positive non-small cell lung cancer (NSCLC). However, almost all patients become resistant to treatment. In some patients, emergence of tertiary EGFR mutations is implicated as a resistance mechanism. This study describes patients with NSCLC who acquired the rare EGFR mutations, L718Q or G724S, following EGFR TKI treatment. Patients and Methods: This was a retrospective, observational study undertaken in France from Feb–Nov 2021, in patients with EGFR mutation-positive NSCLC with an acquired L718Q or G724S mutation. Primary objectives were description of tumor characteristics, progression, and progression under treatment. Results: Nine eligible patients were identified. Acquired resistance to initial EGFR TKI treatment was associated with T790M emergence in six patients, who then received osimertinib monotherapy. Overall, eight patients received osimertinib monotherapy treatment at some point (average treatment duration: 18.3 months). Following the emergence of L718Q or G724S, patients received chemotherapy (n = 4; two of whom subsequently received afatinib), nivolumab (n = 2), afatinib (n = 2), or immunochemotherapy (n = 1). In the four patients who received afatinib after identification of L718Q or G724S, 2 achieved a partial response, one had stable disease and one had progressive disease. Treatment duration was 1.6– 31.7 months. In patients with controlled disease (n = 3), progression-free survival was 6.1– 31.7 months. Two of these patients had previously received osimertinib. Conclusion: Currently, there is no consensus regarding the treatment of EGFR mutation-positive NSCLC following emergence of the osimertinib resistance mutations, L718Q or G724S. Afatinib appears to be a promising treatment option in this setting. Keywords: osimertinib, afatinib, real-world evidence, tertiary EGFR mutations Activating mutations in the epidermal growth factor receptor ( EGFR) gene are present in approximately 10–15% of Caucasian patients with advanced non-small cell lung cancer (NSCLC) of adenocarcinoma histology (11% in France), 1 rising to about 50% in Asian patients. 2 First-line standard of care for these patients comprises monotherapy with an EGFR tyrosine kinase inhibitor (TKI). Three generations of EGFR TKI are available which have different mechanisms of action; the first-generation reversible EGFR TKIs (erlotinib and gefitinib), the second-generation ErbB family blockers (afatinib and dacomitinib), and the third-generation irreversible EGFR TKI, osimertinib. 2 Head-to-head prospective trials have demonstrated the superiority of second- and third-generation TKIs over first-generation EGFR TKIs. 3–5 Based on the Phase III FLAURA trial, 4,6 which demonstrated overall survival (OS) benefit with osimertinib versus erlotinib/gefitinib and favorable tolerability, osimertinib is often used as treatment of choice for EGFR mutation-positive NSCLC. However, disease progression is ultimately inevitable. 7 Most randomized clinical trials of EGFR TKIs have been restricted to patients with so called "common" EGFR mutations, comprising deletions of exon 19 (Del19) and L858R in exon 21; these two mutations represent a large majority of the EGFR mutations detected. 8 Consequently, few prospective data are available to inform treatment decisions for the estimated 7–23% of EGFR mutation-positive NSCLC tumors that harbor uncommon EGFR mutations. 9 Uncommon EGFR mutations are highly heterogeneous. In silico and in vitro observations indicate that the sensitivity of -Abstract Truncated-
oncology,biotechnology & applied microbiology